Pilot trial reports arthritis benefit for Exclzyme Pet in dogs

A newly published pilot trial suggests Exclzyme Pet may help reduce arthritis-related pain and mobility problems in dogs, but the results arrive with the usual caveats that surround the companion animal supplement market. In the Frontiers in Veterinary Science study, researchers found that dogs receiving the supplement for 30 days improved significantly on lameness, mobility, pain, and quality-of-life measures compared with placebo, and they reported no adverse clinical or hematologic events over the study period. (frontiersin.org)

The study enters a crowded but uneven field. Canine osteoarthritis is commonly managed with multimodal care, and supplements are widely used by pet parents, yet the evidence base remains mixed across products and ingredient classes. Cornell’s Riney Canine Health Center notes that many joint supplement claims have historically leaned on limited manufacturer-linked research, though the evidence base is gradually improving. Cornell also stresses that supplements are not regulated like medications, and that veterinarians should guide product choice and use them alongside broader arthritis management strategies when appropriate. (vet.cornell.edu)

In this trial, 26 client-owned dogs with osteoarthritis were enrolled and 23 completed the 30-day study. Dogs were randomized to Exclzyme Pet or placebo, with both products given as 2 g sachets twice daily on an empty stomach. The placebo was maltodextrin, and the paper says the products were matched in appearance to preserve blinding. Pain was assessed with the Helsinki Chronic Pain Index, while veterinarians also evaluated lameness-related clinical parameters and collected hematology and CRP data. (frontiersin.org)

Reported outcomes favored the supplement group across a range of measures. The paper says Exclzyme Pet reduced lameness, weight-bearing difficulty, joint mobility impairment, and pain scores by roughly 52% to 58%, while owner-reported measures such as mood, willingness to play, vocalization, and ease of movement also improved significantly versus placebo. On the biomarker side, CRP fell from 0.68 to 0.30 mg/dL in the treatment group, a 56.1% reduction, while the placebo group’s CRP rose from 0.71 to 0.82 mg/dL; the between-group difference was reported as highly significant. (frontiersin.org)

The paper frames Exclzyme Pet as a multi-enzyme, phytochemical formulation and discusses bromelain and papain as key bioactive components with anti-inflammatory rationale. Still, the study’s commercial context is important. The paper states that funding came from Advanced Enzymes Technologies Ltd., and several authors were employed by Animedics Health India Pvt. Ltd. or other affiliated organizations. The authors also state that the funder was not involved in study design, data collection, analysis, interpretation, or the decision to publish. (frontiersin.org)

Why it matters: For veterinarians, this is encouraging but early evidence. The trial design was stronger than many supplement reports because it was randomized, double-blind, and placebo-controlled, and it paired owner-reported pain scoring with clinician assessment and an inflammatory biomarker. But it was still a pilot study with only 23 completers, a 30-day follow-up, and inherent subjectivity in owner questionnaires, which the authors explicitly note as a limitation. That means the findings may be useful for clinical awareness and client conversations, but they don’t yet establish Exclzyme Pet as a replacement for standard-of-care osteoarthritis management. (frontiersin.org)

That nuance matters in practice because pet parents often ask about supplements before, after, or instead of prescription therapy. Current expert guidance still points clinicians toward individualized multimodal plans that can include weight management, low-impact exercise, rehabilitation, analgesics or anti-inflammatories when indicated, and careful selection of reputable supplement brands. Cornell specifically advises veterinary involvement before starting supplements and notes that products with the NASC seal may offer added confidence in label accuracy, even though that is not the same as drug-style approval. (vet.cornell.edu)

What to watch: The key next signal will be whether Exclzyme Pet can show benefit in larger, independently replicated studies that run longer than 30 days and include more objective endpoints, such as force-plate gait analysis, activity monitoring, rescue-medication use, or longer-term safety follow-up. That’s the level of evidence many clinicians will want before changing routine arthritis recommendations. (frontiersin.org)